文献速递眼整形与眼眶

眼眶淋巴瘤:一项国际多中心回顾性研究

Orbital Lymphoma-An International Multicenter Retrospective Study.
PubMed 文献 · Am J Ophthalmol · 2018-11-10

该研究纳入7个国际眼肿瘤中心1980年至2017年共797例组织学确诊的眼眶淋巴瘤患者,回顾分析亚型分布、治疗与生存。结果显示B细胞来源占98%,EMZL最常见(57%),其次为DLBCL(15%)、FL(11%)和MCL(8%);EMZL和FL预后显著优于DLBCL和MCL。

要点

  • 眼眶淋巴瘤以B细胞来源为主,EMZL最常见,占57%。
  • EMZL和FL的10年疾病特异性生存率分别为92%和71%,显著优于DLBCL(41%)和MCL(32%)。
  • 组织学亚型是眼眶淋巴瘤预后的主要预测因素。

核心结论

  • 眼眶淋巴瘤主要分为EMZL、DLBCL、FL和MCL四种亚型,组织学亚型是预后的主要预测因素。
  • EMZL和FL患者的预后显著优于DLBCL和MCL患者。

研究设计与样本

  • 共纳入797例组织学确诊的眼眶淋巴瘤患者,主要终点为总生存、疾病特异性生存和无进展生存。

主要发现

  • 中位年龄64岁,男性占51%(n=407)。
  • B细胞来源淋巴瘤占98%(n=779)。
  • EMZL最常见(57%,n=452),其次为DLBCL(15%,n=118)、FL(11%,n=91)和MCL(8%,n=66)。
  • EMZL和FL的10年疾病特异性生存率分别为92%和71%,DLBCL和MCL分别为41%和32%。

关键数值与推荐

  • 局限期(Ann Arbor IE期)EMZL和FL常接受外照射放疗。
  • DLBCL、MCL以及播散性EMZL和FL主要接受化疗。

临床怎么用

  • 眼眶淋巴瘤应明确组织学亚型以指导预后判断和治疗选择。
  • 局限期EMZL和FL可考虑外照射放疗,DLBCL、MCL及播散性EMZL和FL以化疗为主。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate and characterize the clinical features of subtype-specific orbital lymphoma. DESIGN: Retrospective, interventional case series. METHODS: The study included 7 international eye cancer centers. Patient data were collected from January 1, 1980 through December 31, 2017. A total of 797 patients with a histologically verified orbital lymphoma were included. The primary endpoints were overall survival, disease-specific survival, and progression-free survival. RESULTS: The median age was 64 years, and 51% of patients (n = 407) were male. The majority of lymphomas were of B-cell origin (98%, n = 779). Extranodal marginal zone B-cell lymphoma (EMZL) was the most frequent subtype (57%, n = 452), followed by diffuse large B-cell lymphoma (DLBCL) (15%, n = 118), follicular lymphoma (FL) (11%, n = 91), and mantle cell lymphoma (MCL) (8%, n = 66). Localized Ann Arbor stage IE EMZL and FL were frequently treated with external beam radiation therapy. DLBCL, MCL, and disseminated EMZL and FL were primarily treated with chemotherapy. EMZL and FL patients had a markedly better prognosis (10-year disease-specific survival of 92% and 71%, respectively) than DLBCL and MCL patients (10-year disease-specific survival of 41% and 32%, respectively). CONCLUSIONS: Four lymphoma subtypes were primarily found in patients with orbital lymphoma: EMZL, DLBCL, FL, and MCL. The histologic subtype was found to be the main predictor for outcome, with EMZL and FL patients having a markedly better prognosis than DLBCL and MCL.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Olsen TG, Holm F, Mikkelsen LH, et al. Orbital Lymphoma-An International Multicenter Retrospective Study. Am J Ophthalmol. 2018. PMID: 30419193. doi:10.1016/j.ajo.2018.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。